View Older Stories View More Recent Stories
-
Waters Corp. (WAT) PT Raised to $370 at BofA Securities
-
Waters Corp. (WAT) Tops Q1 EPS by 39c, provides guidance
-
Barclays: Life science insiders sold $187M in stock during first quarter
-
Waters receives FDA clearance for at-home cervical cancer screening kit
-
Evercore ISI Upgrades Waters Corp. (WAT) to Outperform
-
Evercore: ' Latest Survey Work Positions 2026 As Better Year For Biopharma Spending'
-
Waters Corp. (WAT) files mixed shelf
-
Stifel on Waters Corp. (WAT): 'Choppy Start On The BD Side'
-
Waters Corp. (WAT) PT Lowered to $370 at UBS to Reflect Group Multiple Contraction
-
Waters Corp. (WAT) PT Lowered to $373 at TD Cowen
-
Barclays Resumes Waters Corp. (WAT) at Overweight
-
Waters Corp. (WAT) PT Lowered to $350 at BofA Securities
-
Evercore ISI Resumes Waters Corp. (WAT) at In Line
-
Waters Corp. (WAT) call put ratio 1 calls to 2.9 puts with a focus on ATM February puts
-
BD completes spin-off and merger of biosciences unit with Waters Corp
-
Stifel Reiterates Hold Rating on Waters Corp. (WAT)
-
Waters Corp. (WAT) Tops Q4 EPS by 2c, provides guidance
-
Waters shareholders approve BD biosciences unit combination
-
HSBC Starts Waters Corp. (WAT) at Buy
-
Guggenheim Starts Waters Corp. (WAT) at Buy
-
William Blair Starts Waters Corp. (WAT) at Outperform
-
Wolfe Research Upgrades Waters Corp. (WAT) to Outperform
-
KeyBanc on Life Sciences Tools & Services: 'We Highlight Our Favored 2026 "Tools" Stocks'
-
Morgan Stanley Starts Waters Corp. (WAT) at Equalweight, 'High Quality Core Business but BDX Deal Bears Monitoring'
-
KeyBanc: White House GLP-1 Deals Boost Growth Potential for Key Suppliers
-
Waters Corp. (WAT) PT Raised at TD Cowen on Core Business Strength
-
Waters Corp. (WAT) PT Raised to $375 at BofA Securities
-
Waters Corp. (WAT) call put ratio 1.4 calls to 1 put as share price up 7%
-
Waters Corp. (WAT) Tops Q3 EPS by 19c ; Offers Guidance
-
Waters Corp. (WAT) May options active as share price up 1.5%
-
Rothschild Redburn Starts Waters Corp. (WAT) at Buy
-
Stifel Reiterates Hold Rating on Waters Corp. (WAT)
-
KeyBanc Takeaways from This Year's BioProcess International Conference
-
KeyBanc Reiterates Overweight Rating on Waters Corp. (WAT)
-
Waters Corp. (WAT) PT Lowered to $322 at TD Cowen
-
Waters Corp. (WAT) PT Lowered to $360 at Bernstein SocGen Group
-
Waters Corp. (WAT) PT Lowered to $385 at Jefferies, 'Solid Beat & Raise Still Embeds Upside'
-
Waters Corp. (WAT) Tops Q2 EPS by 1c, provides guidance
-
Waters Corp. (WAT) PT Lowered to $333 at TD Cowen
-
Bernstein on Waters Corp. (WAT): 'Is It Really That Bad?'
-
UBS Reiterates Neutral Rating on Waters Corp. (WAT)
-
Stifel Reiterates Hold Rating on Waters Corp. (WAT)
-
Waters Corp. (WAT) PT Lowered to $330 at BofA Securities
-
Waters to merge with BD's biosciences unit in $17.5 billion deal
-
Waters Corp. (WAT) PT Raised to $465 at Scotiabank
-
Bernstein on US Life Science Tools & Diagnostics: 'Why We're More Bullish...'
-
Bernstein SocGen Group Reiterates Outperform Rating on Waters Corp. (WAT)
-
Waters Corp. (WAT) unveils Alliance iS HPLC System Software 2.0
-
KeyBanc: 'Waters Corp. (WAT) Likely to Continue Outperforming Peers'
-
UBS Reiterates Neutral Rating on Waters Corp. (WAT)

